Hacker News Reader

Thanks for the info. My comment was mostly coming from a place of having read articles like this about how antibiotics don’t really make money for pharmaceutics companies:

https://www.forbes.com/sites/quora/2018/01/02/antibiotics-ar...

View on HN

I see where you're coming from now. ABX (antibiotics) are a bit unique. New ABX are sparingly profitable because they are usually incremental developments instead of new classes of compounds. A new class would be lucrative. I see this as a reflection that ABX dev is a ridiculously hard problem with many failures. There are many working in this area, but not much to show yet.

Reply on news.ycombinator.com